Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Laura Chico

Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying

Vigil Neuroscience tripled Thursday after Sanofi agreed to buy it for $470 million plus a CVR tied to its experimental Alzheimer's treatment.

Investors Business Daily

Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug

Travere Therapeutics reached an agreement Tuesday on what data the FDA would require to approve its drug for a kidney disease.

Investors Business Daily

Travere Therapeutics Hits 16-Month High On A Promising FDA 'Pivot' In Kidney Disease

Travere Therapeutics stock popped Wednesday after a group of experts suggested an alternative means of measuring the success of FSGS drugs.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

Biogen stock has mostly trended sideways this year, but that could soon change with up to $10 billion in dry powder, an analyst said Tuesday.

Investors Business Daily

Jazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure

Jazz stock toppled Thursday — but shares of key rival Praxis surged — after its essential tremor drug failed in midstage testing.

Investors Business Daily

Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision

Top-notch biotech stock Pharvaris surged Monday after the FDA said it could begin testing a treatment for a swelling disorder in people.

Investors Business Daily

The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring

Biotech stock Xenon rocketed Monday, after its experimental epilepsy drug unexpectedly showed promise in depression treatment.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Viridian Wants To Take On Horizon; Why This Update In Thyroid Eye Disease Fell Flat

Shares of VRDN stock collapsed Tuesday after Viridian Therapeutics unveiled the results of its chronic treatment for thyroid eye disease.

Investors Business Daily

Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near

Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi.

Investors Business Daily

Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Investors Business Daily

1 Medical Stock You Shouldn't Touch With a 10-Foot Pole

Apellis Pharmaceuticals’ (APLS) stock has jumped more than 25% year-to-date based on FDA approval for treating geographic atrophy. Despite the breakthrough, the company’s ability to scale up production remains a concern. Moreover, its closest competitor is also close to getting approval. Given its poor financials, stretched valuation, and weak profitability,…

StockNews.com

Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped

A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted.

Investors Business Daily

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm

The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.

Investors Business Daily

Apellis Pharma Crashes On Unexpected Delay For Eye Drug, Taking A Key Rival With It

Apellis reported an unexpected delay for its eye-disease treatment, leading APLS stock to crash and taking shares of Iveric with it.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How These Biotech Players Could Help Treat Covid-Fueled Depression

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

Investors Business Daily

Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win

Karuna Therapeutics topped expectations Monday in a study of its schizophrenia treatment, and the biotech stock soared to a record high.

Investors Business Daily

Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug

The FDA accepted Travere Therapeutics' application for a kidney disease treatment on Monday, leading TVTX stock to surge higher.

Investors Business Daily

Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time'

Pfizer will acquire migraine drugmaker Biohaven Pharmaceuticals for nearly $12 billion in a deal that sent BHVN stock rocketing.

Get all your
news in one place.

100’s of premium titles.
One news app.

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.